AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $222.74, giving the company a market capitalization of 393.54B. It carries a P/E multiple of 107.09 and pays a dividend yield of 3.1%.
As of 2026-06-04, AbbVie(ABBV) stock has fluctuated between $217.13 and $224.50. The current price stands at $222.74, placing the stock +2.6% above today's low and -0.8% off the high.
The AbbVie(ABBV)'s current trading volume is 3.71M, compared to an average daily volume of 5.29M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.
ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...
Analyst ratings
73%
of 33 ratingsMore ABBV News
Key Points Both of these stocks are in the red this year. But they have qualities that can help them bounce back. 10 stocks we like better than AbbVie › Som...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...
The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbbVie wasn't one of them. Get them here FREE . ABBV turned $1,000 into $5,000 over 10 y...
This Is What a $1 Million Dividend Portfolio Pays After Taxes By Joel South Published Jun 3, 7:45AM EDT Quick Read A $1M portfolio anchored by O and SCHD gene...
In recent weeks, AbbVie has secured multiple regulatory wins, including EU approval of AQUIPTA for acute migraine, expanded EU labeling for VENCLYXTO combinatio...
Key Points AbbVie leverages a strong pipeline in immunology and oncology to drive nearly $61.2 billion in annual revenue. Pfizer maintains a diverse portfolio...
The United States market has experienced a notable upswing, climbing 1.6% in the last week and rising 28% over the past year, with earnings expected to grow by...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.